Roche Holding AG (RHHVF)
OTCMKTS · Delayed Price · Currency is USD
338.60
+3.08 (0.92%)
Sep 11, 2025, 2:52 PM EDT
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B CHF
Revenue Growth
+4.80%
P/S Ratio
3.63
Revenue / Employee
614.90K CHF
Employees
103,249
Market Cap
289.56B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |
Roche Holding AG News
- 6 days ago - Roche Holding AG (RHHBY) Gains CE-IVDR Approval for VENTANA HER2 (4B5) Test | RHHBY stock news - GuruFocus
- 6 days ago - New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or ... - GuruFocus
- 6 days ago - Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify ... - GuruFocus
- 6 days ago - Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients - PRNewsWire
- 6 days ago - New data for Roche's Vabysmo reinforce its efficacy, safety and durability in neovascular or “wet” age-related macular degeneration (nAMD) - GlobeNewsWire
- 6 days ago - New Data for Genentech's Vabysmo Reinforce Its Efficacy, Safety and Durability in Wet Age-Related Macular Degeneration (AMD) - Business Wire
- 7 days ago - Roche gets EU CE mark for its Port Delivery platform containing Susvimo - Seeking Alpha
- 7 days ago - Roche receives CE mark for Contivue, its Port Delivery Platform containing Susvimo, for neovascular age-related macular degeneration (nAMD) - GlobeNewsWire